Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 5/2024

Open Access 01-05-2024 | Breast Cancer | Brief Report

SFRP1 decreases WNT-Mediated M2 macrophage marker expression in breast tissue

Authors: Kelly J. Gregory, Holly Mason, Jesse Casaubon, Sallie S. Schneider

Published in: Cancer Immunology, Immunotherapy | Issue 5/2024

Login to get access

Abstract

The Wnt family of secreted proteins are involved in mammary gland development and tumorigenesis. It has recently been shown that Wnt ligands promote M2 macrophage polarization and so we sought to determine the effects of a Wnt signaling antagonist, Secreted Frizzled Related Protein 1 (SFRP1), on M2 marker expression. We measured a murine M2 marker (Arg1) in mice with a targeted deletion of Sfrp1 during different stages of mammary gland development including puberty, pregnancy, and lactation, as well as in response to obesity. Next, to determine whether Wnt signaling/antagonism affects human M2 markers (CD209 and CCL18), we treated a human patient derived explant (PDE) breast tissue sample with exogenous Wnt3a in the presence and absence of rSFRP1. Finally, we expanded our PDE study to 13 patients and performed bulk RNAseq analysis following the treatment described above. We found that in loss of Sfrp1 in the murine mammary gland increased Arg1 expression. Moreover, we showed that Wnt3a increases CD209 and CCL18 mRNA and protein expression in breast PDEs and that their expression is decreased in response to rSFRP1. Our RNAseq analysis unveiled novel genes that were affected by Wnt3a treatment and subsequently reversed when rSFRP1 was added. Validation of these data exhibited that chemokines involved in promoting macrophage polarization and cancer metastasis, including CCL11 and CCL26, were stimulated by Wnt3a signaling and their expression was abrogated by treatment with rSFRP1. Our data suggest that SFRP1 may be an important mediator that tempers Wnt signaling in the tumor microenvironment.
Appendix
Available only for authorised users
Literature
3.
go back to reference Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA (1999) Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem 274(23):16180–16187CrossRefPubMed Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA (1999) Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem 274(23):16180–16187CrossRefPubMed
4.
go back to reference Gregory KJ, Schneider SS (2015) Estrogen-mediated signaling is differentially affected by the expression levels of Sfrp1 in mammary epithelial cells. Cell Biol Int 39(7):873–879CrossRefPubMed Gregory KJ, Schneider SS (2015) Estrogen-mediated signaling is differentially affected by the expression levels of Sfrp1 in mammary epithelial cells. Cell Biol Int 39(7):873–879CrossRefPubMed
8.
go back to reference Klopocki E et al (2004) Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 25(3):641–649PubMed Klopocki E et al (2004) Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 25(3):641–649PubMed
9.
go back to reference Gauger KJ (2013) Mice deficient in Sfrp1 exhibit increased adiposity, dysregulated glucose metabolim, and enhanced macrophage infiltration. PLoS ONE 8(12):e78320CrossRefPubMedPubMedCentral Gauger KJ (2013) Mice deficient in Sfrp1 exhibit increased adiposity, dysregulated glucose metabolim, and enhanced macrophage infiltration. PLoS ONE 8(12):e78320CrossRefPubMedPubMedCentral
14.
go back to reference Leek RD, Harris AL (2002) Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7(2):177–189CrossRefPubMed Leek RD, Harris AL (2002) Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7(2):177–189CrossRefPubMed
19.
go back to reference Gauger KJ, Hugh JM, Troester MA, Schneider SS (2009) Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis. Cancer Cell Int 9:11CrossRefPubMedPubMedCentral Gauger KJ, Hugh JM, Troester MA, Schneider SS (2009) Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis. Cancer Cell Int 9:11CrossRefPubMedPubMedCentral
20.
28.
go back to reference Zhou T, Chen Y, Hao L, Zhang Y (2006) DC-SIGN and immunoregulation. Cell Mol Immunol 3(4):279–283PubMed Zhou T, Chen Y, Hao L, Zhang Y (2006) DC-SIGN and immunoregulation. Cell Mol Immunol 3(4):279–283PubMed
Metadata
Title
SFRP1 decreases WNT-Mediated M2 macrophage marker expression in breast tissue
Authors
Kelly J. Gregory
Holly Mason
Jesse Casaubon
Sallie S. Schneider
Publication date
01-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 5/2024
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-024-03638-0

Other articles of this Issue 5/2024

Cancer Immunology, Immunotherapy 5/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine